GCM
NBIX icon

Graham Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Graham Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,829
Closed -$259K – 1399
2025
Q4 		$259K Sell
1,829
-944
-34% -$137K 0.01% 929
2025
Q3 		$389K Buy
+2,773
New +$376K 0.01% 728
2024
Q4 		– Sell
-24,839
Closed -$2.86M – 1396
2024
Q3 		$2.86M Buy
+24,839
New +$3.41M 0.05% 199
2022
Q4 		– Sell
-10,529
Closed -$1.12M – 1227
2022
Q3 		$1.12M Buy
+10,529
New +$1.07M 0.04% 439

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Graham Capital Management's NBIX Position: Q1 2026 in Review

Graham Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 1,829 shares — an estimated $259K sold.

Graham Capital Management first reported a position in NBIX in Q3 2022 and held it in 4 quarters. The position peaked at $2.86M in Q3 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Graham Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 1,829 Neurocrine Biosciences shares in Q1 2026, an estimated $259K.
  • Graham Capital Management first reported a position in Neurocrine Biosciences in Q3 2022 and held it in 4 quarters.
  • Graham Capital Management's Neurocrine Biosciences position peaked at $2.86M in Q3 2024.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.